PMID- 28323591
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20181202
IS  - 2375-6314 (Print)
IS  - 2375-6314 (Linking)
VI  - 87
IP  - 12
DP  - 2016 Dec 1
TI  - Treatment and Monitoring of Central Serous Chorioretinopathy in Pilots.
PG  - 1041-1044
LID - 10.3357/AMHP.4671.2016 [doi]
AB  - BACKGROUND: Central serous chorioretinopathy (CSC), which has the characteristics 
      of a serous retinal detachment (SRD) in the macular area, affects mostly men in 
      the 30- to 50-yr age range. Some patients have persistent SRD, which may cause 
      retinal thinning and photoreceptor impairment. CSC symptoms are gradual vision 
      loss and/or metamorphopsia. Some commercial airline pilots are concerned about 
      CSC symptoms, which can disqualify them from flying for months and can also 
      reoccur. Thus, careful monitoring and treatment of CSC are critical for pilots, 
      especially those with chronic or recurrent CSC. The Federal Aviation 
      Administration requires uncorrected distant visual acuity in the better eye to be 
      20/200 or better, with correction to 20/20 or better employing lenses of no 
      greater power than +/- 3.5 diopters spherical equivalent. Multimodal imaging 
      modalities such as spectral domain optical coherence tomography (SD-OCT) allow 
      early detection of CSC noninvasively. Moreover, half-dose verteporfin 
      photodynamic therapy (PDT) can cure CSC in the early stage. CASE REPORTS: Five 
      male Japanese commercial airline pilots with CSC are presented. Four of these 
      five pilots had been disqualified from flying for several months, but after 
      receiving half-dose PDT, they were ultimately able to resume flying commercial 
      aircraft. DISCUSSION: Half-dose PDT can rapidly reduce serous subretinal fluid in 
      CSC eyes. Recurrent and/or chronic CSC is seen in clinical cases. Therefore, 
      continuous observation by SD-OCT after half-dose PDT is essential, even if the 
      patient's vision recovers. Early, i.e., before visual acuity decreases, treatment 
      is highly recommended.Shinojima A, Mori R, Fujita K, Yuzawa M. Treatment and 
      monitoring of central serous chorioretinopathy in pilots. Aerosp Med Hum Perform. 
      2016; 87(12):1041-1044.
FAU - Shinojima, Ari
AU  - Shinojima A
AD  - Nihon University Hospital, Chiyoda-ku, Tokyo, Japan.
FAU - Mori, Ryusaburo
AU  - Mori R
FAU - Fujita, Kyoko
AU  - Fujita K
FAU - Yuzawa, Mitsuko
AU  - Yuzawa M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Aerosp Med Hum Perform
JT  - Aerospace medicine and human performance
JID - 101654770
RN  - 0 (Photosensitizing Agents)
RN  - 0 (Porphyrins)
RN  - 0X9PA28K43 (Verteporfin)
SB  - IM
MH  - Adult
MH  - Central Serous Chorioretinopathy/diagnostic imaging/*drug therapy/physiopathology
MH  - Humans
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - *Photochemotherapy
MH  - Photosensitizing Agents/*administration & dosage
MH  - *Pilots
MH  - Porphyrins/*administration & dosage
MH  - Tomography, Optical Coherence
MH  - Verteporfin
MH  - Visual Acuity
EDAT- 2016/01/01 00:00
MHDA- 2017/06/02 06:00
CRDT- 2017/03/22 06:00
PHST- 2017/03/22 06:00 [entrez]
PHST- 2016/01/01 00:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
AID - 10.3357/AMHP.4671.2016 [doi]
PST - ppublish
SO  - Aerosp Med Hum Perform. 2016 Dec 1;87(12):1041-1044. doi: 10.3357/AMHP.4671.2016.